

## 1. IDENTIFICATION

<b>Product Name:</b>	<b>Drax™ Exametazime</b> Kit for the Preparation of Tc-99m Exametazime for Leukocyte Labeling
<b>Product Number:</b>	30000001200/30000002769
<b>Recommended Use:</b>	Diagnostic Medical Agent. Diagnostic radiopharmaceutical imaging agent after reconstitution with radioactive Technetium Tc-99m.
<b>Restrictions for Use:</b>	After reconstitution with Technetium Tc-99m, this material must be handled only by trained health care professionals qualified to handle radioactive material.
<b>Manufacturer:</b>	Jubilant DraxImage Inc. 16751 TransCanada Highway Kirkland, Quebec, Canada, H9H 4J4 Phone: +1-514-630-7080 / 1-888-633-5343 Fax: +1-514-694-9295 / 1-866-431-4288 Hours of operation: 8am-5pm Eastern Time Web site: <a href="http://www.draximage.com">www.draximage.com</a>
<b>Synonyms:</b>	Kit for the Preparation of Technetium Tc-99m Exametazime Injection; Tc-99m Exametazime; Tc-99m HMPAO

## 2. HAZARD IDENTIFICATION

**Classification / Category:** Does not present hazards within the WHMIS/GHS list of physical Hazard Classes.

**Health Hazards:** Not expected to be a health hazard as per the WHMIS/GHS list of Health Hazards. Although some ingredients found in Drax™ Exametazime are skin and eye irritants, due to the small quantities present in the container, no adverse health effects are expected to occur from exposure.

**Label Elements:**  
Symbol: Not applicable  
Signal Word: Not applicable

**Precautions:**  
Read the Package Insert prior to use.  
Promptly remove any contamination from skin, eyes or clothing. Avoid all unnecessary exposure to the chemical substance.

**Eye contact:** Not expected to be a health hazard.  
**Skin contact:** Not expected to be a health hazard.  
**Inhalation:** Not expected to be a health hazard.  
**Ingestion:** Not expected to be a health hazard.  
**Chronic exposure:** Not expected to be a health hazard.  
**Aggravation of pre-existing Conditions:** No information found.

## 3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Ingredients Component (quantity per vial):	CAS #	Wt %
Exametazime (API) (0.5 mg)	105613-48-7	10.0%
Sodium Chloride (4.5 mg)	7647-14-5	89.8%
Stannous Chloride Dihydrate (7.6 µg)	10025-69-1	0.2%

---

**4. FIRST-AID MEASURES**

---

**Eye Exposure:** Wash thoroughly with running water for at least 15 minutes. Get medical advice if irritation develops.

**Skin Exposure:** Wash exposed area with soap and water. Get medical advice if irritation develops.

**Inhalation:** Not expected to require first aid measure; remove to fresh air, support breathing by usual methods if necessary.

**Ingestion:** Not expected to require first aid measure; call physician if necessary.

**Most Important Symptoms and Effects, Acute and Delayed:** Not applicable

**Immediate Medical Attention and Special Treatment:** Not applicable

---

**5. FIRE FIGHTING MEASURES**

---

**Fire Extinguishing Media:** Use media suitable for extinguishing surrounding fire.

**Specific Hazards Arising from the Product:** None

**Special Instructions:** There are no specific fire fighting instructions relative to this product. In the event of a fire, wear full protective clothing and NIOSH-approved self-contained breathing apparatus with full facepiece operated in the pressure demand or other positive pressure mode.

---

**6. ACCIDENTAL RELEASE MEASURES**

---

Collect non-radioactive spills and dispose of material as non-hazardous waste.

**For Drax™ Exametazime Reconstituted with Sodium Pertechnetate Tc-99m:** If any loss or release of the radioactive contents occurs, notify your Radiation Safety Officer. All cleanup operations should be performed according to the Standard Operating Procedures (SOP) for radiation protection established for your facility and by the CNSC, NRC, or other applicable local, provincial, state or federal regulations.

Refer to the Canadian Nuclear Safety Commission Radionuclide Information Booklet at [http://www.nuclearsafety.gc.ca/pubs\\_catalogue/uploads/Radionuclide-Information-Booklet-2016-eng.pdf](http://www.nuclearsafety.gc.ca/pubs_catalogue/uploads/Radionuclide-Information-Booklet-2016-eng.pdf) for information on Tc-99m.

---

**7. HANDLING AND STORAGE**

---

There are no specific safety-related requirements for storage. However the drug should be stored at room temperature [15-25 °C (59-77 °F)] before reconstitution with sodium pertechnetate Tc-99m. Refer to the Package Insert and product labeling for specific approved storage temperature ranges.

**For Drax Exametazime Reconstituted with Sodium Pertechnetate Tc-99m,** the product should be shielded and stored at room temperature [15-25 °C (59-77 °F)].

Handling devices such as syringe shields and tongs should be used. Storage and disposal of the reconstituted radioactive product should be controlled in a manner that is in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.

---

**8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

---

**For Tin Compounds:**

Airborne Exposure Limits	OSHA Permissible Exposure Limit (PEL)	ACGIH® Threshold Limit Value (TLV®)
Stannous Chloride Dihydrate (7.6 µg/vial)	2 mg/m <sup>3</sup> (TWA), as Sn	2 mg/m <sup>3</sup> (TWA), as Sn

TWA = Time Weighted Average

**Engineering Controls:** Not expected to require any special ventilation.

**Respiratory Protection:** Not expected to require personal respirator usage.

**Skin Protection:** Wear protective gloves and clean body-covering clothing.

**Eye/Face Protection:** Safety glasses.

---

---

## 9. PHYSICAL AND CHEMICAL PROPERTIES

---

**Appearance:** White powder or white plug in a 10 mL colorless glass vial

**Odour:** Odourless.

**Odour Threshold:** Not applicable

**pH:** 9.0 – 9.8 when reconstituted

**Melting Point:** ca. 0 °C (32 °F) reconstituted

**Freezing Point:** ca. 0 °C (32 °F) reconstituted

**Initial Boiling Point and Boiling Range:** ca. 100 °C (212 °F) reconstituted

**Flash Point:** Not applicable

**Evaporation Rate:** Not applicable

**Solubility:** Soluble in water

---

## 10. STABILITY AND REACTIVITY

---

**Reactivity:** Not applicable

**Chemical Stability:** Stable under recommended conditions of use and storage.

**Possibility of Hazardous Reactions:** Not expected to occur.

**Conditions to Avoid:** None under recommended conditions of use and storage.

**Incompatible Materials:** None reasonably foreseeable.

**Hazardous Decomposition Products:** When heated to decomposition, substance may emit oxides of carbon and nitrogen as well as corrosive fumes of hydrochloric acid.

---

## 11. TOXICOLOGICAL INFORMATION

---

For detailed toxicological information on specific components, write to the address listed in Section 1 – Attn: Regulatory Affairs Department.

### Stannous Chloride Dihydrate

#### **Acute Toxicity:**

##### Oral Data

LD50: 700 mg/kg (rat)

##### Intravenous Data

LD50: 7830 mg/kg (rat)

**Teratogenicity:** Species: rat; dose: 3 mg/kg; route of application: oral; exposure time: 7-12 days pregnant

Result: Specific developmental abnormalities: craniofacial (including nose and tongue).

**Mutagenicity:** Species: human; dose: 10 µmol/l; cell type: leukocyte

Mutation test: DNA damage

Species: hamster; dose: 50 µmol/l; cell Type: ovary

Mutation test: DNA damage

#### **Reproductive and Developmental Toxicity:**

Species: rat; dose: 3 mg/kg; route of application: oral; exposure time: 7-12 days pregnant

Effects on Embryo or Fetus: Fetal death.

Effects on Fertility: Post-implantation mortality (e.g., dead and/or resorbed implants per total number of implants).

**Carcinogenicity:** No long term animal studies have been performed to evaluate carcinogenic potential or whether Technetium Tc-99m Exametazime Injection affects fertility in males or females.

None of the components present in this material at concentrations equal to or greater than 0.1 % are listed by IARC, NTP, OSHA, or ACGIH® as a carcinogen. When this kit is reconstituted with radioactive material, this product contains a substance known to the State of California to cause cancer.

---

## 12. ECOLOGICAL INFORMATION

---

Because this product is intended for use by hospital or clinic patients, it is expected to be treated by standard wastewater treatment facilities with no adverse environmental impacts.

---

## 13. DISPOSAL CONSIDERATIONS

---

Drax™ Exametazime reconstituted with Sodium Pertechnetate Tc-99m is Radioactive Waste until the activity has decayed to non-detectable levels. Radioactive Waste must be handled in accordance with procedures established by your Radiation Safety Officer, NRC, CNSC, and any other applicable regulations. If medical waste is involved, such as blood, blood products, or sharps, the waste must be handled as a Biohazard and disposed of accordingly. If not radioactive or a Biohazard, Drax™ Exametazime is considered non-hazardous. Consult local, provincial, state, or federal regulations for proper disposal.

---

## 14. TRANSPORTATION INFORMATION

---

**U.S. Department of Transportation Regulations (DOT):** Not regulated in the non-radioactive form.

**International Air Transport Association (IATA):** This product does not meet the definition of dangerous goods, and is therefore exempt from IATA/ICAO regulations.

---

## 15. REGULATORY INFORMATION

---

### **CERCLA Reportable Quantities:**

When this kit is reconstituted with radioactive material, the Reportable Quantity for Tc-99m = 100 Ci (3.7 E 12 Bq). Releases to air, land or water of these hazardous substances which exceed the Reportable Quantity (RQ) must be reported.

SARA Title III

302 Extremely Hazardous Substances: None

311/312 Hazard Categories: None

313 Toxic substances subject to annual release reporting requirements: None

RCRA Hazardous Waste Status: Non-hazardous (See Section 13 for additional details).

California Proposition 65 Warning: When this kit is reconstituted with radioactive material, this product contains a substance known to the State of California to cause cancer.

Australian Hazchem Code: None allocated.

Australian Poison Schedule: None allocated.

NFPA Ratings: Health: 0 Flammability: 0 Reactivity: 0

WHMIS: This Safety Data Sheet (SDS) has been prepared according to the Workplace Hazardous Materials Information Systems (2015) requirements of the Hazardous Products Regulations (HPR) and the SDS contains all of the information required by the HPR.

---

## 16. OTHER INFORMATION

---

Revision Information: Rev. 2, November 27, 2017

This document pertains, in most part, to the non-radioactive, non-reconstituted, lyophilized product. Once reconstituted with radioactive Tc-99m, the material falls under the regulation of the CNSC, NRC, or other local, provincial, state, or federal agencies. Only trained professionals in licensed facilities are permitted to handle the radioactive reconstituted product.

Refer to the Canadian Nuclear Safety Commission Radiation Radionuclide Information Booklet at [http://www.nuclearsafety.gc.ca/pubs\\_catalogue/uploads/Radionuclide-Information-Booklet-2016-eng.pdf](http://www.nuclearsafety.gc.ca/pubs_catalogue/uploads/Radionuclide-Information-Booklet-2016-eng.pdf) for information on Tc-99m.

SDS – Drax™ Exametazime

Jubilant DraxImage Inc. provides the information contained herein in good faith but makes no representation as to its comprehensiveness or accuracy. This document is intended only as a guide to the appropriate precautionary handling of the material by a properly trained person using this product. Individuals receiving the information must exercise their independent judgement in determining its appropriateness for a particular purpose. Jubilant DraxImage Inc. MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE INFORMATION SET FORTH HEREIN OR TO THE PRODUCT TO WHICH THE INFORMATION REFERS. ACCORDINGLY, Jubilant DraxImage Inc. WILL NOT BE RESPONSIBLE FOR DAMAGES RESULTING FROM USE OF OR RELIANCE UPON THIS INFORMATION.

Jubilant DraxImage Inc., dba Jubilant Radiopharma a subsidiary of Jubilant Pharma  
Revision 2